Putting Science to Work

In the News

  • Syngene Q3 net profit up 6 pc to Rs 87 cr

    Business Standard- 22/01/2019. Consolidated total revenue of the company stood at Rs 484.4 crore for the quarter under consideration as against Rs 399.3 crore for the same period a year ago.


  • First of its kind symposium on Next Gen Ab Platforms

    Biospectrum- 06/12/2018. The symposium was hosted under the aegis of “INNO”, a platform that aims to facilitate knowledge-sharing among scientists across industry and academia.


  • Syngene International net up by 1.7% in Q2

    PharmaBiz- 25/10/2018. Both our Discovery Services and Dedicated Centre verticals performed well, with the later benefiting from expansions announced earlier in the year of our collaboration with Baxter.


  • Syngene International Q1 net profit up 6% at Rs 66 crore

    PharmaBiz- 26/07/2018. The quarter saw good performance within biologics manufacturing, discovery services and chemical development services as well as a benefit from improved FX rates.


  • Syngene expands agreement with Baxter

    India Infoline- 23/07/2018. Syngene and Baxter originally established the Baxter Global Research Center in 2013. The duration of the new agreement has now been extended until 2024.


  • Artelo Biosciences Enters Into Global R&D Partnership With Syngene International And Aptus Clinical For The Clinical Development Of ART27.13 In Oncology

    Cision PR Newswire- 12/06/2018. As part of the agreement, Syngene will be the discovery and development partner providing a pre-clinical data package to support the advancement of ART27.13 for anti-cancer indications.


  • Syngene teams with immuno-oncology firm to provide greater value-added services

    Out Sourcing Pharma- 04/06/2018. As per the partnering agreement, Syngene will screen target antigens Zumutor’s human antibody libraries to identify and characterize novel antibody clones- which it will further develop towards novel biotherapeutics programs.


  • An Exclusive Interview with Jonathan Hunt – CEO, Syngene International, India by Pharma Boardroom

    Pharma Boardroom- 24/05/2018. Syngene International, one of the fastest growing and leading contract research and manufacturing organizations in the world, discusses the company’s unique ecosystem of innovation...


  • Syngene International Q4 net rises 8% to Rs 84 crore

    Money Control-25/04/2018. During FY18, the company's net profit increased by 6 percent at Rs 305 crore and revenue by 17 percent at Rs 1,485 crore.


  • /Media/Default/images/infd.jpg
    Syngene enters pact with GSK to provide drug discovery services

    Money Control-27/03/2018. As part of the agreement, Syngene will set-up a customized discovery research laboratory to support projects across several therapeutic areas.


Discovery Chemistry Discovery Biology Safety Assessment Large Molecule Development Chemical Development Formulation Development Stability Studies Polymer Research Integrated Discovery & Development Clinical Development Services Bioinfomatics Antibody Drug Conjugates Oligonucleotide Synthesis Contact Us

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

Social Widget